All In Biotech

NDA 022314 · Novartis

Exforge Hct

Amlodipine Besylate, Hydrochlorothiazide, Valsartan · Oral · Thiazide Diuretic; Angiotensin 2 Receptor Blocker

Last checked: Nov 20, 2026Latest source record: Sep 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Apr 30, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

3,664

3,408 serious, 502 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Exforge HCT as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Oct 28, 2026.

Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Exforge HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes...

Mechanism: The active ingredients of Exforge HCT target 3 separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; valsartan blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume. A more detailed description of the mechanism of action of each individual component follows....

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • EXFORGE HCT · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE HCT · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE HCT · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 25MG; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood pressure increased378
  • death256
  • hypertension231
  • wrong technique in product usage process227
  • malaise210
  • off label use191
  • diabetes mellitus188
  • dizziness175
  • drug ineffective174
  • headache173
  • blood pressure decreased170
  • fatigue146

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20094
201048
2011158
2012310
2013216
2014228
2015205
2016262
2017211
2018252
2019252
2020346
2021386
2022335
2023237
202485
202569
202660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Exforge HCT (Amlodipine/Valsartan/HCThiazid)

2024 spending

$650K

Beneficiaries

227

993 claims

Per beneficiary

$2,865

$12.16 per unit

View as table
YearSpending
2020$923,253
2021$1,412,847
2022$1,512,540
2023$988,025
2024$650,350

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,807 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.